Acute lung injury and other serious complications of Plasmodium vivax malaria

Tan, Lionel; Yacoub, Sophie; Scott, Sarah E.; Bhagani, Sanjay; Jacobs, Michael

doi:10.1016/s1473-3099(08)70153-1

Cited by 102 publications

(65 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Severe and fatal vivax malaria has been reported from Indonesia, 52,53 Papua New Guinea, 54 India, 55 and Brazil. 56,57 The main manifestations are anemia and respiratory distress, 53,[56][57][58][59][60][61][62] although series of patients with coma, shock, and renal and hepatic dysfunction associated with vivax malaria have also been described. [55][56][57]61,62 Plasmodium vivax is very sensitive to artemisinin and its derivatives.…”

mentioning

confidence: 99%

Diagnosis and Treatment of Plasmodium vivax Malaria

Baird

Maguire

Price

2012

Advances in Parasitology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Diagnosis and Treatment of Plasmodium vivax Malaria

Baird

Maguire

Price

2012

Advances in Parasitology

View full text Add to dashboard Cite

show abstract

“…Previous work has suggested that vivax-associated lung dysfunction may occur from an inflammatory response in the pulmonary microvasculature, exacerbated by treatment [27], causing increased capillary permeability, alveolar endothelial damage and chest X-ray infiltrates [28][29][30]. One infant had an acute respiratory distress-type picture.…”

Section: Discussionmentioning

confidence: 96%

Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia

Douglas

Pontororing²,

Lampah³

et al. 2014

BMC Medicine

View full text Add to dashboard Cite

Background: Plasmodium vivax causes almost half of all malaria cases in Asia and is recognised as a significant cause of morbidity. In recent years it has been associated with severe and fatal disease. The extent to which P. vivax contributes to death is not known. Methods: To define the epidemiology of mortality attributable to vivax malaria in southern Papua, Indonesia, a retrospective clinical records-based audit was conducted of all deaths in patients with vivax malaria at a tertiary referral hospital. Results: Between January 2004 and September 2009, hospital surveillance identified 3,495 inpatients with P. vivax monoinfection and 65 (1.9%) patients who subsequently died. Charts for 54 of these 65 patients could be reviewed, 40 (74%) of whom had pure P. vivax infections on cross-checking. Using pre-defined conservative criteria, vivax malaria was the primary cause of death in 6 cases, a major contributor in 17 cases and a minor contributor in a further 13 cases. Extreme anaemia was the most common primary cause of death. Malnutrition, sepsis with respiratory and gastrointestinal manifestations, and chronic diseases were the commonest attributed causes of death for patients in the latter two categories. There were an estimated 293,763 cases of pure P. vivax infection in the community during the study period giving an overall minimum case fatality of 0.12 per 1,000 infections. The corresponding case fatality in hospitalised patients was 10.3 per 1,000 infections. Conclusions: Although uncommonly directly fatal, vivax malaria is an important indirect cause of death in southern Papua in patients with malnutrition, sepsis syndrome and chronic diseases, including HIV infection.

show abstract

“…The inflammatory response which occurs during the P.vivax infection is greater than that which is seen in the P. falciparum infection, with a similar or a greater parasite load [33]. The cytokine production which occurs during the infection is higher than that which is seen in the P. falciparum infection [34]. We could not draw comparisons between the proportions of se vere malaria and P.vivax malaria, as only the sick vivax malaria cases were studied.…”

Section: Discussionmentioning

confidence: 98%